Cafaro A, Caputo A, Fracasso C, Maggiorella M T, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo M L, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Buttò S, Heeney J, Verani P, Titti F, Ensoli B
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
Nat Med. 1999 Jun;5(6):643-50. doi: 10.1038/9488.
Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.
迄今为止，旨在阻断病毒进入的疫苗策略未能诱导出针对异源病毒的保护作用。因此，控制病毒感染和阻止疾病发作可能是人类免疫缺陷病毒（HIV）疫苗策略更可实现的目标。在此，我们表明用具有生物活性的HIV-1 Tat蛋白对食蟹猴进行疫苗接种是安全的，可引发广泛的（体液和细胞）特异性免疫反应，并将高致病性猿猴-人类免疫缺陷病毒（SHIV）-89.6P的感染降低到检测不到的水平，防止CD4 + T细胞减少。这些结果可能为开发抗艾滋病疫苗提供新的机会。
